Image Place holder

Nikhil I. Khushalani, MD

Vice Chair, Department of Cutaneous Oncology

Specialty: Medical Oncology
Program: Cutaneous Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Cancer Types Treated: Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Skin Cancer (Nonmelanoma)

Dr. Khushalani is the Vice Chair for the Department of Cutaneous Oncology at Moffitt Cancer Center. Dr. Khushalani’s clinical interest is the development of novel therapeutics for people diagnosed with melanoma and other skin cancers. He is greatly interested in the treatment of uveal melanoma, and melanoma that has metastasized to the brain. Dr. Khushalani is interested in research on angiogenesis in melanoma and the translation of findings into clinical therapeutics. He is studying the economic impact of new melanoma drugs on healthcare (pharmacoeconomics) with an aim to devise strategies to reduce cost. Dr. Khushalani earned his MD from Topiwala National Medical College, University of Bombay, in Maharashtra, India. He completed an Internal Medicine Residency at the State University of New York (SUNY) at Buffalo, where he also served as Chief Resident. He completed a Medical Oncology Fellowship at Roswell Park Cancer Institute in 2002. Dr. Khushalani was Assistant Professor of Oncology at Roswell Park Cancer Institute and, prior to joining the Moffitt team, was Associate Professor of Medicine at SUNY, Buffalo, where he was the Section Chief of Soft Tissue and Melanoma Medicine, and Director of the IL-2 Program.       

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • Roswell Park Cancer Institute - Medical Oncology

Residency:

  • KEM Hospital and Seth GS Medical Collage - Internal Medicine
  • State University of New York - Internal Medicine

Medical School:

  • T.N. Medical College University of Bombay - MBBS
Participating Trials

CLINICAL TRIAL 18933
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition:
Intervention: Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18874
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
Condition:
Intervention: BMS-936558 (Nivolumab); HBI-8000 (chidamide); Nivolumab
Open

CLINICAL TRIAL 18309
A Phase 2, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Condition:
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; Not Applicable; Proleukin (Interleukin-2); TIL
Open

CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18975
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Condition:
Intervention: REGN2810
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18597
Phase I Study of Escalating Doses of XL888 with Vemurafenib plus Cobimetinib for Patients with Unresectable BRAF Mutated Stage III/IV Melanoma
Condition:
Intervention: Cobimetinib; RO5185426 (Vemurafenib); Vemurafenib (Zelboraf); XL888
Open

CLINICAL TRIAL 19310
A Phase III, Open-Label, Multicenter,Two-Arm, Randomized Study To Investigate The Efficacy And Safety Of Cobimetinib Plus Atezolizumab Versus Pembrolizumab In Patients With Previously Untreated Advanced Brafv600 Wild-Type Melanoma
Condition:
Intervention: Atezolizumab (Tecentriq); Cobimetinib; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition:
Intervention: Not Applicable; TSR-033; TSR-042
Open

CLINICAL TRIAL 19381
PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Condition:
Intervention: DTIC (Dacarbazine); Dacarbazine; Not Applicable; PV-10; Talimogene Laherparepvec (OncoVEX); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Temodal (Temozolomide); Temozolomide
Open

CLINICAL TRIAL 19396
A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma
Condition:
Intervention: IMO-2125; Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 19127
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab Followed by Nivolumab Monotherapy
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19441
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Condition:
Intervention: Cobimetinib; Not Applicable; RO5185426 (Vemurafenib); Vemurafenib (Zelboraf)
Open

CLINICAL TRIAL 19485
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma
Condition:
Intervention: IMCgp100
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition:
Intervention: BMS-936558 (Nivolumab); NKTR-214; Nivolumab
Open

CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Nktr-214 And In combination With Nktr-214 Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Condition:
Intervention: BMS-936558 (Nivolumab); NKTR-214; NKTR-262; Nivolumab
Open

CLINICAL TRIAL 19475
Phase 2 Study of Ceritinib in Patients with Unresectable Melanoma
Condition:
Intervention: Ceritinib (Zykadia)
Open

CLINICAL TRIAL 19601
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Condition:
Intervention: BMS-936558 (Nivolumab); BMS-986213; Nivolumab; Not Applicable
Open

CLINICAL TRIAL 19634
Study of Resistance Mechanisms to Checkpoint Blockade
Condition:
Intervention:
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Oyasiji T, Tan W, Kane J, Skitzki J, Francescutti V, Salerno K, Khushalani NI. Malignant adnexal tumors of the skin: a single institution experience. World J Surg Oncol. 2018 May;16(1):99. Pubmedid: 29848318. Pmcid: PMC5977488.
  • Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar;8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
  • Khushalani NI. Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?. J Clin Oncol. 2018 Jun;36(17):1649-1653. Pubmedid: 29389234.
  • Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul;379(4):341-351. Pubmedid: 29863979.
  • Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018 Feb;36(4):383-390. Pubmedid: 28671856.
  • Pokuri VK, Tomaszewski GM, Ait-Oudhia S, Groman A, Khushalani NI, Lugade AA, Thanavala Y, Ashton EA, Grande C, Fetterly GJ, Iyer R. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial. Am J Clin Oncol. 2018 Apr;41(4):332-338. Pubmedid: 27014931.
  • Sreeraman Kumar R, Thapa R, Kim Y, Khushalani NI, Sondak VK, Reed DR. Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials. Cancer Med. 2018 Apr;7(4):991-996. Pubmedid: 29478277. Pmcid: PMC5911596.
  • Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 inhibition in patients with unresectable V600E mutant melanoma. Clin Cancer Res. 2018 Apr. Pubmedid: 29674508.
  • Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol. 2017 Sep;80(3):497-505. Pubmedid: 28702772.
  • Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017 Apr;75:47-55. Pubmedid: 28214657.
  • Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. J Natl Compr Canc Ne. 2017 Apr;15(4):473-482. Pubmedid: 28404758.
  • Sondak VK, Khushalani NI. Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma. Int J Radiat Oncol Biol Phys. 2017 05;98(1):16-17. Pubmedid: 28586957.
  • Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb;2(2):234-240. Pubmedid: 26633184.
  • Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016 Dec;27(12):2288-2294. Pubmedid: 27637745.
  • Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec;4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
  • Jarkowski A, Hare R, Loud P, Skitzki JJ, Kane JM, May KS, Zeitouni NC, Nestico J, Vona KL, Groman A, Khushalani NI. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature. Am J Clin Oncol. 2016 Dec;39(6):545-548. Pubmedid: 24879468.
  • Luu C, Khushalani NI, Zager JS. Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opin Biol Ther. 2016 Dec;16(12):1491-1499. Pubmedid: 27602429.
  • Khushalani NI, Sondak VK. Are we there yet? Prolonged MAPK inhibition in BRAF(V600)-mutant melanoma. Lancet Oncol. 2016 09;17(9):1178-1179. Pubmedid: 27480104.
  • Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000380. Pubmedid: 27148567. Pmcid: PMC4850888.
  • Oxenberg J, Khushalani NI, Salerno KE, Attwood K, Kane JM. Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection. J Surg Oncol. 2015 Jun;111(7):829-833. Pubmedid: 25772798.
  • McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb;21(3):561-568. Pubmedid: 25424850. Pmcid: PMC4315731.
  • Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375-384. Pubmedid: 25795410.
  • Saraceni MM, Khushalani NI, Jarkowski A. Immunotherapy in Melanoma: Recent Advances and Promising New Therapies. J Pharm Pract. 2015 Apr;28(2):193-203. Pubmedid: 24674910.
  • Jarkowski A, Nestico JS, Vona KL, Khushalani NI. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings. J Oncol Pharm Pract. 2014 Feb;20(1):47-50. Pubmedid: 23512270.
  • Jarkowski A, Khushalani NI. BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog. 2014 Feb;13:1. Pubmedid: 24737949. Pmcid: PMC3986540.
  • Nurkin SJ, Nava HR, Yendamuri S, LeVea CM, Nwogu CE, Groman A, Wilding G, Bain AJ, Hochwald SN, Khushalani NI. Outcomes of endoscopic resection for high-grade dysplasia and esophageal cancer. Surg Endosc. 2014 Apr;28(4):1090-1095. Pubmedid: 24232046.
  • Iyer R, Chhatrala R, Shefter T, Yang G, Malhotra U, Tan W, Levea C, Robins M, Khushalani N. Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial. Oncology-Basel. 2013 Sep;85(1):53-58. Pubmedid: 23860007.
  • Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc . 2012 Mar;10(3):366-400. Pubmedid: 22393197.
  • Damodaran S, Bellavia T, Sait SN, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clin Colorectal Cancer. 2012 Jun;11(2):151-154. Pubmedid: 22133502.
  • Jarkowski A, Hare R, Francescutti V, Wilkinson N, Khushalani N. Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor. Anticancer Res. 2011 Oct;31(10):3429-3432. Pubmedid: 21965757.
  • May KS, Yang GY, Khushalani NI. The role of radiation in the perioperative treatment of esophagogastric cancer. CURR TREAT OPTION ON. 2011 Mar;12(1):61-71. Pubmedid: 21267682.
  • Yang GY, May KS, Iyer RV, Chandrasekhar R, Wilding GE, McCloskey SA, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M, Thomas CR. Renal atrophy secondary to chemoradiotherapy of abdominal malignancies. Int J Radiat Oncol Biol Phys. 2010 Oct;78(2):539-546. Pubmedid: 20133075.
  • Puthillath A, Mashtare T, Wilding G, Khushalani N, Steinbrenner L, Ross ME, Romano K, Wisniewski M, Fakih MG. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol Hematol. 2009 Sep;71(3):242-248. Pubmedid: 19081732.
  • Yang GY, McClosky SA, Khushalani NI. Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers. Gastrointest Cancer Res. 2009 Mar;3(2 Suppl 1):S6-S10. Pubmedid: 19461922. Pmcid: PMC2684733.
  • Khushalani N. Cancer of the esophagus and stomach. Mayo Clin Proc. 2008 Jun;83(6):712-722. Pubmedid: 18533089.
  • Ramnath N, Yu J, Khushalani NI, Gottlieb RH, Schwarz JK, Iyer RV, Rustum YM, Creaven PJ. Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anticancer Drugs. 2008 Aug;19(7):749-752. Pubmedid: 18594219.